Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease

Inflammatory Bowel Disease

Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab

doi: 10.1097/MEG.

Inflammatory Bowel Disease

Characteristics and Long-Term Outcomes of Pregnancy-Onset Inflammatory Bowel Disease: A Case-Control Study

Inflamm Bowel Dis.

Yu A, Friedman S, Ananthakrishnan AN

doi: 10.1093/ibd/izaa096.

Inflammatory Bowel Disease

Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry

Inflamm Bowel Dis.

Casanova MJ, Chaparro M, Mínguez M, Ricart E, Taxonera C, García-López S, Guardiola J, López-San Román A, Iglesias E, Beltrán B, Sicilia B, Vera MI, Hinojosa J, Riestra S, Domènech E, Calvet X, Pérez-Calle JL, Martín-Arranz MD, Aldeguer X, Rivero M, Monfort D, Barrio J, Esteve M, Márquez L, Lorente R, García-Planella E, de Castro L, Bermejo F, Merino O, Rodríguez-Pérez A, Martínez-Montiel P, Van Domselaar M, Alcaín G, Domínguez-Cajal M, Muñoz C, Gomollón F, Fernández-Salazar L, García-Sepulcre MF, Rodríguez-Lago I, Gutiérrez A, Argüelles-Arias F, Rodriguez C, Rodríguez GE, Bujanda L, Llaó J, Varela P, Ramos L, Huguet JM, Almela P, Romero P, Navarro-Llavat M, Abad Á, Ramírez-de la Piscina P, Lucendo AJ, Sesé E, Madrigal RE, Charro M, García-Herola A, Pajares R, Khorrami S, Gisbert JP

doi: 10.1093/ibd/izz192.

Inflammatory Bowel Disease

Early Discontinuation of Infliximab in Pregnant Women With Inflammatory Bowel Disease

Inflamm Bowel Dis.

Truta B, Leeds IL, Canner JK, Efron JE, Fang SH, Althumari A, Safar B

doi: 10.1093/ibd/izz250.

Inflammatory Bowel Disease

Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases

United European Gastroenterol J.

Liefferinckx C, Verstockt B, Gils A, Tops S, Van Moerkercke W, Vermeire S, Franchimont D

doi: 10.1177/2050640619841538.

Inflammatory Bowel Disease

Systematic Review with Meta-analysis: The Impact of Co-occurring Immune-mediated Inflammatory Diseases on the Disease Course of Inflammatory Bowel Diseases

Inflamm Bowel Dis.

Attauabi M, Zhao M, Bendtsen F, Burisch J

doi: 10.1093/ibd/izaa167.

Inflammatory Bowel Disease

Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study

Therap Adv Gastroenterol.

Grob L, Bluemel S, Biedermann L, Fournier N, Rossel JB, Vavricka SR, Zeitz J, Rogler G, Stallmach A, Scharl M

doi: 10.1177/1756284819895217.

Inflammatory Bowel Disease

Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring

Aliment Pharmacol Ther.

Lucidarme C, Petitcollin A, Brochard C, Siproudhis L, Dewitte M, Landemaine A, Bellissant E, Bouguen G

doi: 10.1111/apt.15046.

Inflammatory Bowel Disease

Efficacy of Granulocyte and Monocyte Adsorptive Apheresis in Patients with Inflammatory Bowel Disease Showing Lost Response to Infliximab

J Crohns Colitis.

Yokoyama Y, Sawada K, Aoyama N, Yoshimura N, Sako M, Hirai F, Kashiwagi N, Suzuki Y

doi: 10.1093/ecco-jcc/jjaa051.

Related content

Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab

Characteristics and Long-Term Outcomes of Pregnancy-Onset Inflammatory Bowel Disease: A Case-Control Study

Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry

Early Discontinuation of Infliximab in Pregnant Women With Inflammatory Bowel Disease

Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases

Systematic Review with Meta-analysis: The Impact of Co-occurring Immune-mediated Inflammatory Diseases on the Disease Course of Inflammatory Bowel Diseases

Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study

Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring

Efficacy of Granulocyte and Monocyte Adsorptive Apheresis in Patients with Inflammatory Bowel Disease Showing Lost Response to Infliximab